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Background. Accurate assessment of irradiated neck in squamous cell carcinoma of the head and neck (HNSCC) is essential. Fine-
needle aspiration cytology is often performed for suspicious lesions but it is limited by its low negative predictive value (NPV). We
postulated that F-18 fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET/CT)
can overcome this limitation by its highNPVvalue and allow for amore accurate assessment of irradiated neck inHNSCC.Methods.
Fifty-four HNSCC patients were included for the study. They all received previous irradiation to the neck. Clinical characteristics,
details of radiotherapy, PET/CT results, follow-up findings, and final histological diagnosis were analyzed. Results.The sensitivity,
specificity, positive predictive value (PPV), and NPV were 95.8%, 96.7%, 95.8%, and 96.7%, respectively. Age, sex, radiation dose,
interval between PET/CT and radiotherapy completion, nature of radiotherapy, and use of second course of radiotherapy were
not found to affect diagnostic accuracy of PET/CT. A new algorithm for investigation of masses in irradiated neck is proposed.
Conclusions. PET/CT is an effective diagnostic tool and has a complementary role to FNAC in the management of irradiated neck
in head and neck cancers, particularly in cases where suspicious lesions were identified but FNAC showed negative results.
1. Background
Radiotherapy is frequently employed in the management of
head and neck squamous cell carcinoma (HNSCC). Locore-
gionally advanced tumours are frequently given adjuvant
radiotherapy with or without chemotherapy to improve
locoregional control. Definitive radiation is also given for
organ preservation and to avoid operative morbidity.
Accurate assessment of irradiated neck is essential in
management of HNSCC. Unfortunately, radiation-associated
fibrosis of skin and subcutaneous tissue can easily mask
underlying lesions on clinical examination. Various modal-
ities of imaging were used to detect residual or recurrent
neck diseases. However, anatomical distortion caused by
radiotherapy (and often together with surgery) renders that
the assessment of disease status by imaging alone is difficult.
Ideally, when a suspicious lesion is identified clinically
or radiologically, tissue biopsy should be sampled from
suspicious lesions. In reality, however, they are often lim-
ited by inaccessibility and/or potential morbidity associated,
especially in irradiated necks. Thus, fine-needle aspiration
cytology (FNAC) is often performed instead. However, we
have recently shown that while its positive predictive value
(PPV) is high (89%), negative predictive value (NPV) of
FNAC is rather low (37%) in irradiated necks [1]. The low
NPVof FNACnecessitated an alternativemean of assessment
in these cases.
We know that cancer cells are hypermetabolic with
increased glucose metabolism [2]. F-18 fluorodeoxyglucose
(FDG), as an analogue of glucose, accumulates in such
lesions, allowing their detection by positron emission tomog-
raphy (PET). A low FDG uptake is suggestive of the absence
of cancer tissues, as these tissues, by definition, involve
unregulated cell growth which requires a lot of energy from
cell metabolism. We can therefore expect a high NPV in PET
for detecting malignancy.
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On the other hand, various normal structures in the
neck region, such as muscles, salivary glands, thyroid glands,
and vocal cords, have variable FDG uptake and can lead
to false positivity. Benign hypermetabolic processes, such as
inflammation, can cause similar confusion in interpretation.
The interpretation is even more difficult in patients with
previous treatments. For instance, free jejunal flaps used in
reconstruction of circumferential pharyngectomy defect can
contain hypermetabolic lymphadenopathy in their mesen-
teric pedicles [3]. Likewise, vocal cord paralysis fromprevious
surgery can cause compensatory effort in the normal cord and
result in increased FDG uptake. PPV of PET may be lowered
by all these factors.
When performed alone, PET is limited by its spatial
resolution and lack of anatomic details which hinder precise
tumor localization. Hence, combined PET-computed tomog-
raphy (PET/CT) is often performed instead to overcome
these shortcomings. PET/CT allows for reliable coregistra-
tion of anatomical and functional imaging data. It permits
accurate tumour localization and facilitates identification
of physiologic uptake. As a sole mean of neck assessment,
PET/CT may be limited by its PPV and lack of cytopatho-
logical diagnosis, but, together with the high PPV of FNAC,
these investigations may complement each other and allow
for an accurate assessment of irradiated necks.
We reviewed our experience with PET/CT in manage-
ment of irradiated neck in an attempt to elucidate the
diagnostic performance. Other factors that may potentially
affect the diagnostic outcomes were also reviewed.
2. Methods
A computer search was performed to identify all patients
who have been treated under the Division of Head and
Neck Surgery, Department of Surgery, QueenMary Hospital,
from January 2008 to December 2011, with histologically
proven HNSCC. We retrospectively retrieved all patients
who had PET/CT performed. Only patients who received
previous irradiation to the neck were included. Nonma-
lignant cases, cases of cutaneous malignancies, and other
types of malignancy (including salivary gland tumours and
nasopharyngeal carcinoma) were excluded. Individual case
notes were searched manually and electronically to retrieve
details on clinical history, radiotherapy, and pathological
results.
PET/CT imaging from skull base through the abdomen
was performed 60minutes following an intravenous injection
of 7 to 15mCi FDG and intravenous contrast. These scans
were then interpreted by a board-certified radiologist as
positive or negative for cervical metastatic disease.
2.1. Reference Standard. Whenever histological diagnosis is
available (either by excisional biopsy or neck dissection),
it was treated as the reference standard. In cases when
radiographic evaluation suggested no cervical metastasis and
no tissue sampling was performed, negative clinical and
radiological follow-up for at least 6 months was considered
as evidence of absence of disease.
2.2. ExclusionCriteria. Patientswere excluded if theymet any
one of the following criteria: (1) radiotherapy, chemotherapy,
or targeted therapy was given during the period between
the PET/CT and histological diagnosis; (2) in cases of
negative PET/CT finding without tissue sampling, radio-
therapy/chemotherapy/targeted therapy was given within 6
months after PET/CT; (3) in cases of negative PET/CT
findings without tissue sampling, a follow-up period less than
6months; (4) no histological diagnosis for cases with positive
PET/CT findings.
Patient’s age, gender, site of primary tumour, details of
radiotherapy, PET/CT results, follow-up findings, and final
histological diagnosis were retrieved.
A PET/CT was defined as “positive” when the radiologist
suspected metastatic cervical disease based on increased
metabolic activity, usually with a SUVmax over 3.
True positive (TP) was defined as positive PET/CT
findings with positive final histology. True negative (TN) was
defined as negative PET/CT findings with either a negative
final histology or a minimum of 6-month negative clinical
and radiological follow-up. False negative (FN) referred to
cases with negative PET/CT findings but subsequent histo-
logical diagnosis of malignancy. False positive (FP) referred
to cases with positive PET/CT findings, but subsequent
histology showed no malignancy. The sensitivity (TP/[TP +
FN]), specificity (TN/[TN + FP]), positive predictive value
(TP/[TP + FP]), and negative predictive value (TN/[TN +
FN]) were calculated.
Data were analyzed with SPSS version 18.0 (SPSS, Inc.,
Chicago, IL, USA). Univariate comparisons of diagnostic
outcomes were performed with chi-square test for nominal
variables and logistic regression for continuous variables. A
𝑃 value of 0.05 or less was considered significant.
3. Results
Table 1 summarized the demographics and clinical char-
acteristics of the 54 patients included. The median age
at time of PET/CT was 60 years (range 27–88). Male-to-
female ratio was 2.4 to 1. The commonest site of primary
tumor was the oral cavity, followed by oropharynx and
hypopharynx/cervical oesophagus. Six patients had tumours
at multiple sites along the head and neck region.
Apart from radiotherapy, 33 patients (66%) had previous
neck dissection. Forty-four patients (81%) received previous
chemotherapy. The median interval between PET/CT scan
and time of completion of radiotherapy was 8 months (range
0–369).
There was only one case of false positive and one case of
false negative findings in our series. The overall sensitivity,
specificity, PPV, and NPV were 95.8%, 96.7%, 95.8%, and
96.7%, respectively (Table 2).
Age, sex, radiation dose, interval between PET/CT and
radiotherapy completion, nature of radiotherapy (primary
versus adjuvant treatment), and use of second course of
radiotherapy were not found to affect diagnostic accuracy of
PET/CT (Table 3).
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Table 1: Patient demographics and clinical characteristics (𝑁 = 54).
Median age (range) 60 (27–88)
Sex (M : F) 2.4 : 1
Site of primary tumour
Oral cavity 30 (55%)
Oropharynx 9 (17%)
Hypopharynx/cervical oesophagus 9 (17%)
Multiple sites 6 (11%)
Previous treatment
Neck dissection 33 (61%)
Chemotherapy 44 (81%)
Table 2: Overall accuracy of PET/CT in irradiated neck.
Positive predictive value (PPV) 95.8%




Assessment of disease status in irradiated necks can be
very challenging. Clinical examination often reveals fibrotic
neck which can easily mask any underlying lesion. Conven-
tional imaging, such as ultrasound, computed tomography
(CT) or magnetic resonance imaging (MRI), is difficult to
interpret. Radiotherapy renders indistinct tissue planes and
its associated edema in early postradiotherapy period may
produce an apparent increase in volume to further complicate
interpretation. If there were previous operations as well, neck
dissection and various forms of reconstruction can distort
normal anatomy and make conventional imaging even more
confusing. Rate and lesion of lesion growth have been used
by many as the criteria for recurrence, but it has been shown
that such growth can occur as normal postirradiation effect
[4]. On the other hand, in actual cases of recurrence, such
approach potentially delays diagnosis and treatment.
PET/CT with FDG has been shown to be useful in
diagnosing, staging, and restaging HNSCC [5]. Reduced
FDG uptake was shown to correlate with a reduction in the
number of viable tumor cells in early study [6]. PET as a
mean for staging HNSCC has shown promising results with
sensitivity and specificity for detecting cervical lymph node
involvement up to 90% and 96%, respectively [7, 8]. The
greatest strength of PET/CT is its ability to evaluatemetabolic
changes, independent of the lesion size. Such properties are
particularly useful in detecting residual or recurrent disease
after treatment. PET was reported to have sensitivities and
specificities in the ranges of 96%–100%and 72%–93% [9, 10],
respectively, for surveillance of recurrent HNSCC.
Our study has shown that PET/CT has high PPV (95.8%)
and NPV (96.7%) in irradiated neck irrespective of nature of
treatment (primary RT versus adjuvant RT), dosage, or inter-
val between PET/CT and RT completion. Given its superior
diagnostic ability overmost conventional imagingmodalities,
PET/CT should ideally be employed in all HNSCC patients
requiring assessment of irradiated neck. In reality, however,
the need for neck assessment after irradiation is not uncom-
mon inHNSCC patients and funding for a universal PET/CT
assessment policy is impractical due to its high cost, at least in
our locality and inmost developing countries.There is limited
evidence in current literature on economic evaluation of
PET/CT in HNSCC patients. Studies have been conducted to
evaluate roles of PET/CT in detecting occult neck metastasis
in N0 patients [11], detecting distant metastasis in advanced
disease [12, 13], and restaging recurrent laryngeal cancers [14].
To the best of our knowledge, no study has been performed
to evaluate the cost-effectiveness of PET/CT in assessment of
irradiated neck in HNSCC patients.
To take advantage of the diagnostic accuracy of PET/CT
in limited resources, a realistic diagnostic strategy is neces-
sary to selectively offer PET/CT to those most in need of it
and substitute PET/CT with more affordable alternatives in
the remaining patients. We have recently shown that FNAC
for irradiated neck masses is a safe, cheap, and effective
diagnostic tool with a PPV up to 89%.However, it was limited
by its unacceptably low NPV (37%) [1]. In our locality, a
PET/CT would cost around $3,000, whereas a cytological
evaluation of FNAC specimen would cost only around $100.
FNAC, with ultrasound guidance if necessary, is performed
by clinicians, most of the time in our centre.
In an attempt to strike a balance between cost and
diagnostic accuracy, we proposed a new algorithm for investi-
gation of masses in irradiated neck taking advantages of both
tests (Figure 1). All masses in irradiated necks are subjected
to FNAC assessment initially. When FNAC shows a positive
finding, treatment should be given accordingly as FNAC
has a high PPV. However, when FNAC shows a negative
result, malignancy cannot be reliably ruled out since the
NPV of FNAC is low (37%). PET/CT is then performed
in these patients. Should the PET/CT be negative, its high
NPV (96.7%) will give clinicians more confidence in taking
a conservative approach. On the other hand, if the PET/CT
turns out to be positive, its high PPV (95.8%) may justify a
more aggressive mean in obtaining a pathologic diagnosis,
such as an excisional biopsy. With this algorithm, we believe
that PET/CT and FNAC complement each other in the
management of irradiated neck in head and neck cancers.
Our study is limited by its retrospective nature. Patholog-
ical diagnosis was not available in all patients. Occasionally,
patients with positive radiological findings with gross clinical
sign of advancedmalignancy were decided for palliative care.
Tissue biopsies are not taken from these patients to avoid
unnecessary suffering. These patients represent a group of
“true positive” data that we have excluded. Excluding them
may have lowered the PPV.
5. Conclusion
PET/CT is an effective diagnostic tool and has a comple-
mentary role to FNAC in the management of irradiated
neck in head and neck cancers. In particular, it is useful in
guiding management in cases where suspicious lesions were
identified, but FNAC showed negative results.
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Table 3: Factors affecting diagnostic accuracy of PET/CT in irradiated neck.
Sensitivity Specificity PPV NPV
Sex .699 .374 .699 .374
Age .652 .354 .507 .491
RT dose .906 .958 .622 .191
Interval between PET/CT and RT completion (months) .578 .759 .099 .626
Nature of RT (primary versus adjuvant treatment) .328 .460 .328 .193
Second course of RT .470 .850 .470 .850

























Figure 1: Proposed algorithm for investigation of neck mass in irradiated neck. See [1].
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